Clinical

Videos

Julie Vose, MD, MBA, a professor of internal medicine in the Division of Oncology and Hematology at the University of Nebraska Medical Center discussed the benefits of CAR T-cell for patients with follicular lymphoma. 

Julie Vose, MD, MBA, on the Use of CAR T-Cell Therapy in Lymphomas

Articles

For patients with large B-cell lymphoma who have undergone treatment with axicabtagene ciloleucel, ctDNA monitoring may help to improve early detection of recurrent disease.

ctDNA Monitoring May Improve Early Relapse Detection in Large B-Cell Lymphoma Following Axi-Cel Treatment

Patients in the ZUMA-7 trial who were assigned Yescarta (axicabtagene ciloleucel) saw event-free survival by 60% compared to patients who were on a chemotherapy plus stem cell regimen.

ZUMA-7 Trial Meets Event-Free Survival End Point in Large B-Cell Lymphoma

Bayer seeks FDA approval for its agent copanlisib in combination with rituximab for the treatment of patients with indolent non-Hodgkin lymphoma. 

Application for Copanlisib/Rituximab Combo Submitted to FDA for Indolent NHL

The addition of lenalidomide to rituximab continued to improve survival outcomes with durable responses among patients with indolent B-cell non-Hodgkin lymphomas and mantle cell lymphomas.

Lenalidomide Plus Rituximab Continues to Improve PFS With Manageable Safety in Lymphoma Subtypes

Phase 1 data presented at 2021 EHA indicate that a high rate of response was associated with zandelisib plus zanubrutinib therapy in patients with relapsed/refractory B-cell malignancies and chronic lymphocytic leukemia. 

Zandelisib/Zanubrutinib Combination in R/R CLL and B-Cell Malignancies Shows Clinical Benefit

The CAR T-cell therapy lisocabtagene maraleucel resulted in better efficacy versus standard of care with no new safety signals.

Liso-Cel Meets Primary End Point of Event-Free Survival Improvement in Phase 3 Trial

The combination of mosunetuzumab plus polatuzumab vedotin showed positive efficacy and safety data in a phase 1b study of patients with B-cell non-Hodgkin lymphoma.

Mosunetuzumab Plus Polatuzumab Vedotin to Treat R/R B-NHL Effective and Well Tolerated

An observational cohort study revealed that BEAM therapy led to subpar outcomes compared with thiotepa-based treatment for patients requiring conditioning regimens for primary central nervous system lymphoma. 

Thiotepa Conditioning Regimens Improve Survival in Primary Central Nervous System Lymphoma

An off-the-shelf cellular therapy that combines Epstein Barr Virus–Specific T cells and a CD30-targeting chimeric antigen receptor product demonstrated safety and early efficacy in a group of patients with CD30-positive lymphomas. 

Lymphoma | Topics